Tamtam Try Tamtam free
Natera logo

Natera account plan

cfDNA testing for health

At a glance

Natera is a US cell-free DNA diagnostics company in oncology, women's health and organ health, with $2,306.1 million of FY2025 revenues.

Natera is a diagnostics company whose cell-free DNA tests detect tumour DNA (Signatera), fetal DNA (Panorama) and donor DNA in transplant rejection (Prospera), backed by carrier screening and genomic profiling. Tests run in its own CLIA laboratories in Austin, San Carlos and Boulder, and 95% of 2025 revenues came through its US direct sales force; products are also offered in over 80 countries via laboratory partners. FY2025 total revenues were $2,306.1 million (+35.9%) with a net loss of $208.2 million. It had 6,140 employees at the end of 2025, about 6,500 by November 2026, and is a US-listed company (NTRA).

Business units

Strategic priorities

Grow Signatera volume and price
Management calls the MRD market significantly underpenetrated and targets a long-term path to $2,000 Signatera ASP, from approximately $1,290 in Q3 2026, through more Medicare coverage and guideline inclusion.
$6 billion 2029 target
The CEO says the 2029 target rests on oncology volume and ASP, global markets including Japan, pharma and data, and slightly more modest non-oncology growth.
Clinical evidence
Natera keeps funding trials to win guidelines and coverage, with breast cancer trial investment now exceeding over $250 million and 25 abstracts at ESMO in 2026.
Early cancer detection
The FIND study is fully enrolled with 30,000 patients in the PMA cohort, with a readout in 2027; the multi-cancer early detection assay received FDA Breakthrough Device designation.
Pharma and data services
Pharma MRD demand in the first three quarters of 2026 was already up roughly 70% over all of 2025; management expects pharma and data to contribute several hundred million dollars in 2029.
Japan
The bladder indication was approved in Q3 2026 and colorectal and bladder pricing is being discussed with the health ministry.

Latest results

In Q3 2026 total revenues were $794.0 million, up 34.1% from $592.2 million, on higher volume and average selling prices; gross margin was 64.7% and the net loss narrowed to $59,912 thousand from $87,544 thousand. Approximately 1,093,100 tests were processed (+22.3%) and oncology tests processed rose 60.9%. Over nine months revenues were $2,243.4 million (+36.7%). Natera raised 2026 revenue guidance to $3.005 billion - $3.035 billion (previously $2.850 billion - $2.910 billion), with gross margin of approximately 64% to 66% and positive cash flow. Cash, cash equivalents and restricted cash were $1,097.2 million at September 30, 2026.

Investments and deals

Foresight Diagnostics acquisition
Closed December 4, 2025 for total consideration of $424.5 million, adding phased-variant MRD technology, lymphoma, and the Boulder laboratory.
R&D and clinical trials
2026 R&D is guided at $825 million to $925 million; Q3 2026 R&D rose 39.8% to $242,433 thousand, including early cancer detection, which the CFO calls more than $100 million in spend that generates zero revenue.
Signatera Genome
An upgrade with phased and structural variants and an LOD95 below one part per million, described as the most significant upgrade to Signatera since launch.
Headcount and lab capacity
Headcount increased by approximately 1,200 over the first nine months of 2026 to support lab operations, R&D, clinical trials and billing; 2025 investing included $106.2 million of property and equipment and new leases in Austin and Pleasanton.

Challenges and risks

Reimbursement and prior authorisation
Natera depends on insurers and Medicare; prior-authorisation requirements have hit billing and margins, and many payers do not reimburse microdeletions screening.
Litigation
Natera is appealing a $292.5 million Guardant false-advertising verdict and a $57.0 million Ravgen patent verdict, and faces a $44.9 million CareDx verdict.
Competition and pricing
It names competitors including Guardant Health, Exact Sciences, Tempus Labs, BillionToOne, Labcorp and CareDx, and may not keep its price premium; sequencers and many reagents are sole-sourced.
Continued net losses
The accumulated deficit is $3.0 billion and management expects to continue to incur net losses while investing heavily.
LDT regulation
Most products are laboratory developed tests exposed to possible active FDA regulation.

What leadership says

“you're not going to see any big radical change. We want to stick to the formula that's worked for us.”

Solomon Moshkevich, Chief Executive Officer · Q3 2026 earnings call, 2026-11-05, his first as CEO

“MRD testing is not only about finding recurrence earlier. It can also help avoid overtreatment, including major surgeries as well as systemic therapy.”

Solomon Moshkevich, President (now CEO) · Q1 2026 earnings call, 2026-05-07

“We feel like we are just getting started.”

Steve Chapman, then Chief Executive Officer · Q1 2026 earnings call, 2026-05-07

“We have deployed a significant amount of AI capability around the business in the last year.”

Michael Brophy, Chief Financial Officer · Q1 2026 earnings call, 2026-05-07

Where a supplier can help

Billing and payer operations
Prior authorisation and reimbursement are stated challenges and headcount was added in billing; revenue-cycle, prior-auth automation and payer-analytics tools fit.
Lab automation and supplies
Volume growth above 20% and a cost focus on automation and reagent use create demand for lab automation, logistics and second-source supplies.
Clinical trial services
Heavy investment in trials, from breast cancer to the FIND early detection study, opens room for CROs, site networks and trial-data platforms.
Pharma and real-world data
The pharma and data push on a real-world data asset of over half a million patients needs data infrastructure, privacy and analytics partners.
International expansion
The Japan launch and global markets in the 2029 target call for regulatory, market-access and distribution partners.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Natera?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Natera

What does Natera do?

Natera runs cell-free DNA tests for oncology (Signatera), women's health (Panorama, Horizon) and organ health (Prospera) in its own US laboratories.

What is Natera's revenue?

FY2025 total revenues were $2,306.1 million (+35.9%); Q3 2026 revenues were $794.0 million, and 2026 guidance is $3.005 billion - $3.035 billion.

How many employees does Natera have?

6,140 at the end of 2025 and about 6,500 as of November 2026.

Who leads Natera?

Solomon Moshkevich became CEO and President on November 5, 2026, succeeding Steve Chapman; co-founder Matthew Rabinowitz is Executive Chairman and Michael Brophy is CFO.

What is Natera's strategy?

Grow Signatera volume and price through coverage and evidence, expand into Japan and pharma and data services, and develop early cancer detection, toward a $6 billion 2029 target.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)